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Does whole-cell pertussis vaccine protect
black South African infants?
Assessment of post-vaccination events and antibody responses to
pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3
A. RAMKISSOON, H. M. COOVADIA, W. E. K. LOENING, M. NDLOVANA
Summary
The whole-cell pertussis vaccine currently used in South
Africa has not been adequately evaluated for post-vaccination
events and immunogenicity. A trial of this vaccine combined
with diphtheria and tetanus toxoids (DTP) was undertaken in
115 black babies who received primary vaccination at 2, 4
and 6 months of age. Serological IgG responses to the major
antigens of Bordetella pertussis, filamentous haemagglutinin
(FHA), pertussis toxin (PT) and fimbriae (agglutinogens 2 and
3 (AGG 2 + 3), were evaluated by enzyme-linked
immunosorbent assay in sera obtained at birth, and before
vaccination at 2,4 and 6 months and at 9 months. Surprisingly,
after 3 doses of DTP, responses to PT and FHA were found
merely to restore levels of IgG to PT and FHA to those found
in cord blood. In contrast with the positive increases in these
antibodies found in other series of whole-cell vaccination, the
anti-PT seroconversion rate was only 19% and the anti-FHA
rate only 24%. High levels of anti-AGG 2 + 3 were produced
with 67,2% seroconversion.
The frequency and nature of post-vaccination events were
recorded. Incidences of all reactions to the vaccine were low
(7,6%): Fever (3,2%) and excessive crying (2,4%) were the
most frequenUy occurring minor events. The rate of neuro-
logical post-vaccination events (without sequelae) during the
brief follow-up period was 2 hypotonic-hyporesponsive
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episodes (8,03/1 000 doses) and 1 convulsion (4,02/1000
doses).
Significant pertussis antibody levels were found in maternal
and cord sera with levels in the latter frequently being higher.
Three cases of pertussis occurred during the study period.
Only 1 of the subjects had completed primary vaccination. In
view of these findings, the need for a proper efficacy and
safety study of the currently used DTP vaccine is urgently
indicated in South Africa.
S Atr Med J 1991; 79: 645·649.
Penussis (whooping cough) remains a major cause of morbidity
and mortality in the very young. According to World Health
Organisation estimates, 60000 deaths due to penussis occur
yearly in Africa, vinually all in unvaccinated infants. 1
Conventional whole-cell penussis vaccines at present used
in most parts of the world consist of inactivated cells of
Bordecella percussis and are therefore a mixture of antigens,
some of which, while essential for protection, also produce
adverse reactions. These are considered the most reactive of
childhood vaccines used in routine vaccination schedules,
although the possible contribution of the diphtheria and tetanus
components of triple vaccines is frequently ignored. Whole-
cell vaccines are associated with a wide range of side-effects,
which include local and systemic reactions and some tempo-
rally associated neurological disorders. 2 Use of the vaccine was
discontinued, for example, in Japan after the sudden death of
recently vaccinated infants and in Sweden where protection
after vaccination with unabsorbed vaccine was poor and side-
effects unacceptable.
The safety and efficacy of whole-cell penussis vaccines have
been the subject of discussion in medical publications for the
past decade. Efficacy rates ranging from 20% to 95% have been
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reported throughout the world.3 The best evidence that they
are indeed effective in reducing morbidity and mortality in
pertussis is the increased incidence of the disease and epidemics
that follow withdrawal of vaccine usage.4-6 It is widely recog-
nised that the benefits of effective vaccination outweigh the
risks.
Pertussis vaccines vary from country to country, as do
vaccination schedules and recommendations, and clinical
monitoring techniques. Vaccine efficacy appears to be good in
some areas of South Mrica, but for other areas there is no
information and recent outbreaks of the disease have occurred
in Cape Town and Durban.7 The disease is not notifiable in
South Mrica and consequently no hard data on efficacy have
been reported. There has also been no assessment of responses
to the South Mrican whole-eell pertussis vaccine. We therefore
undertook to assess post-vaccination events and to measure
serum IgG antibody responses to three major antigens, pertussis
toxin (PT), fJ1amentous haemagglutinin (FHA), and fimbrial
agglutinogens 2 and 3 (AGG 2 + 3) in recipients of this
vaccine. Maternal antibodies were also measured, since little is
known about maternofetal transfer of pertussis antibodies,
especially in Mrican countries where inhibition of placental
transfer might occur for a variety of reasons.
Subjects and methods
In the 3-month period March - May 1988, 115 healthy full-
term newborn infants from KwaMashu, a suburb of Durban
inhabited exclusively by blacks, were enrolled in the study
after parental informed consent was ·obtained.
The subjects formed part of a larger study of the antibody
responses and symptoms to the acellular Japanese J-NIH-6
whQOping cough vaccine.8 The subjects received BCG and
trivalent oral polio vaccine (TOPV) at birth and were asked to
return at 2, 4, 6 and 9 months of age. Whole-cell DTP and
TOPV were administered at the time of the 2-, 4- and 6-
month visits in accordance with current WHO recommenda-
tions. Measles vaccine was administered at 9 months of age.
Blood samples were taken before vaccination at each visit.
Three deaths, which were not vaccine-related, occurred before
the subjects were 2 months old. All had been assigned to the
whole-cell vaccine.group and had therefore received only BCG
and TOPV at birth. Of the 112 remaining subjects, 91 (81%)
returned at 2 months of age, 83 (74%) at 4 months, 75 (67%) at
6 months and 60 (54%) at 9 months of age.
This was an open uncontrolled study. All healthy, full-term
babies born at the Polyclinic in KwaMashu, during the period
of enrolment were recruited into the study providing wrinen
parental consent was obtained and that they resided in an area
suitable for follow-up. Babies were assigned to one of three
vaccination groups in sequence. Each group comprised 115
children. Two groups received acellular pertussis vaccine and
one group received whole-cell pertussis vaccine as detailed
above. Mothers and nursing staff were unaware of which
vaccine was given.
Each child was weighed and examined by a paediatrician
(H.M.C. and W.E.K.L.) at every visit before vaccination.
Children with acute illnesses were vaccinated after the illness
subsided. The children were also carefully monitored for
illnesses up to 9 months of age.
Nutritional status of subjects was assessed at each clinic'visit
by the anthropometric indices of length and weight for age,
and clinical feanlres of protein-energy malnutrition, and vitamin
or trace element deficiencies. The US National Center for
Health Statistics Reference Population was used as a standard.
Children with a weight-for-age less than the third centile were
considered underweight and children with a length-for-age
less than 90% of the fiftieth centile were considered stunted.9
An illustrated questionnaire was given to all parents to
record post-vaccination events for a period of at least 14 days
after each vaccination. Detailed instructions pertaining to inter-
pretation of the questionnaire were conveyed in Zulu by one
of us (M.N.). Eight symptoms and signs were registered, viz.
fever; loss of appetite; excessive crying; fretfulness; convulsions;
hypotonic hyporesponsive episodes; swelling or induration at
injection site (irrespective of size); or other symptoms regarded
as possibly vaccine-associated. Fever was measured qualitatively
(mothers' impression) because of the limited educational back-
ground of the population. Convulsions and hypotonic-hypo-
responsive episodes were explained in some detail by M.N.
Before the second and third doses of DTP the parents were
questioned about any side-effects that had occurred after the
previous injection. The parents were instructed to inform the
paediatricians in charge of the trial immediately in case of
serious reactions (usually through M.N.).
A sample of the mother's blood and the cord blood was
obtained for each infant. Whole blood samples were also taken
at 2, 4 and 6 months of age, immediately before vaccination. A
fifth sample was taken at 9 months of age. Sera obtained from
these samples were coded and frozen at -20°C until antibody
assays could be performed. All sera from one individual were
tested in the same assays on the same day. In some cases the
sample was not sufficient to carry out all the tests required and
therefore the numbers of samples giving rise to the data shown
in the tables are not uniform.
IgG antibodies to FHA, PT and AGG 2 + 3 were assayed
by enzyme-linked imrilUnosorbent assay (ELISA) at the Centre
for Applied Microbiology and Research, Public Health Labora-
tory Service, Porton, UK, by one of us (A.R.)~ The ELISA
procedure used was essentially as described by Runer er al. lD
Concentrations of antigens and conjugate used were determined
by chequerboard titrations. .
Materials
The adsorbed DTP vaccine used was manufactured by the
South Mrican Institute for Medical Research, Johannesburg.
The vaccine was made up of 50 LF/ml diphtheria toxoid, 12
LF/ml tetanus toxoid, 20000 million B. perrussis/ml; 2,5
mglml aluminium phosphate (adjuvant) and 0,01% thiomerosol
(preServative). The vaccine was given to the infants in 0,5 ml
doses by intramuscular injection in the left thigh at 2, 4 and 6
months of age. A single lot (No. A595) was used. The date of
manufacture was 1 January 1988 and date of expiry 1 January
1990.
FHA and PT used as antigens in the ELISA were purchased
from the Research Foundation for Microbial Diseases of Osaka
University, Japan. Co-purified AGG 2 + 3 was provided by
Dr A. Robinson, Centre for Applied Microbiology and
Research, UK.
The Japanese reference pertussis antiserum was a gift from
the Research Foundation for Microbial Diseases of Osaska
University, Japan. It was supplied from a single lot and
contained 250 ELISA units of PT-IgG antibody and 400
ELISA units of FHA IgG antibody to penussis/ml. The
reference serum was assigned a value of 400 ELISA units/ml
of anti-AGG 2 + 3. The unitage of the test serum relative to




Three cases of suspected whooping cough occurred in fe~ale
infants. The fust case occurred in a subject 2 months after the
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first dose of vaccine was administered, i.e. at 4 months of age.
'The infant presented with subconjunctival haemorrhage and
tough of 1 week's duration. The second case occurred in an
Imvaccinated infant who was 2 months of age. The third case
occurred in an 8-month-old infant who had been fully vac-
tinated (3 doses of vaccine). No clinical signs of pertussis
occUrred in the latter two babies. Diagnosis was made retro-
;pectively and based on the rapid rise in levels of all three
:antibodies. All infants had marked increases followed by rapid
decline in levels of all three antibodies at the time of suspected
tJertussis infection.
The highest incidence of common childhood infections
IJCcurred between 6 and 9 months of age (68,3% of cases);
infections of the upper respiratory tract were the most common
(15,5% of infections), followed by skin infections (6,8%) and
infections of the gastro-intestinal tract (3,2%) (Table I).
whole-eell pertussis vaccination. The number of post-vaccina-
tion events was very low (Table 11). These subjects appeared
normal on subsequent clinical examination. Fever (3,2%) and
excessive crying (2,4%) were the most frequent systemic reac-
tions. No infant had a local symptom (swelling or induration)
at the injection site, which is most unusual. Other than local
symptoms, post-vaccination events were transient and all
responded to simple treatment at home without any sequelae.
Three neurologically associated post-vaccination events
occurred. One male infant experienced febrile convulsions as
well as a cough with wheeze, within 7 days after the third dose
of vaccine. He was admitted to hospital 30 days later with
measles and bronchopneumonia. No neurological sequelae
resulted. Two hypotonic-hyporesponsive episodes (collapse,
shock) occurred within 7 days after the first dose of vaccine. It
was not possible to ascertain the exact time after vaccination at
which these three events occurred.
Nutritional status
A total of 6 children were found to be malnourished at
various times during the study. Two children were underweight
at birth but recovered before the first vaccination at 2 months
of age. One child was underweight and stunted at 2 months of
age, 2 children were underweight at 6 and 9 months of age.
Their nutritional status had all reverted to normal by the next
clinic visit. One child developed protein-energy malnutrition
at 6 months of age and was still malnourished at 9 months of
age.
Immune response
Transplacental transfer ofpertussis antibodies
Antibodies to all 3 antigens tested were present in relatively
high quantities in maternal sera and often detected in higher
quantities in cord blood (hence active transfer across the
placenta occurred) (Table Ill). All mothers had relatively high
levels of IgG antibody to FHA and AGG 2 + 3. Only 7% of
mothers had very low levels of IgG anti-PT, i.e. < 5 U.
Post-vaccination events
Parental evaluation of post-vaccination events occurring in
the 14 days after vaccination was available for 249 doses of
Filamentous haemagglutinin and pertussis toxin
Geometric mean titres (GMT) (V) of IgG anti-FHA and
IgG anti-PT in cord blood and at 2, 4, 6 and 9 months of age
are shown in Tables III and IV.
TABLE I. INCIDENCE OF INFECTION IN BLACK INFANTS FROM BIRTH TO 9 MONTH~ OF AGE
0<2 moo (N= 91) > 2 < 4 moo (N = 83) > 4 < 6 moo (N = 75) > 6 <: 9 moo (N = 60) Total
Type of infection No. % No. % No. % No. % No. %
Upper respiratory tract 4 4,4 11 13,2 12 16,0 21 35,0 48 15,5
Skin 2 2,2 5 6,0 7 9,3 7 11,7 21 6,8
Gastro"intestinal tract 0 2 2,4 4 5,3 4 6,7 10 3,2
Lower respiratory tract 0 4 4,8 0 5 8,3 9 2,9
Eye 1 11,0 0 2 2,7 0 3 1,0
Measles 0 0 0 2 3,3 2 0,7
Viral meningitis 0 0 0 1 1,7 1 0,3
Pyrexia of unknown origin 0 0 ...0.. 1 1,3 0 1 0,3
Chicken pox 0 0 0 1 1,7 1 0,3
Total 7 7;t 22 26,'5 26 34,7 41 68,3 96 . 31,1
0 0 2 0,8
0 1 1,3 2 0,8
0 0 1 0,4
0 1 1,3 1 0,4
0 0 0
0 0 0










TABLE 11. POST-VACCINATION EVENTS AFTER WHOLE-CELL PERTUSSIS VACCINATION
Dose 1 (N = 91) Dose 2 (N = 83) Dose 3 (N = 75) Total (N = 249)
~ % ~ % ~ % ~ %
4 4,4 3 3,6 1 1,3 8 3,2









Swelling at injection site
Tenderness at injection site
Total
648 SAMJ VOL 79 1 JUN 1991
TABLE Ill. MATERNAL ANDCORD BLOOD LEVELS
(GMT ± SEM)* OF PERTUSSIS ANTIBODIES (RANGE)
Antibody Mothers blood Cord blood
Anti-PT -lgG 41,6 ± 6,5 48,2 ± 9,8
(2,3 - 211,4) (1,4 - 466,6)
(N= 55) (N= 56)
Anti-FHA - IgG 72,2 ± 12,1 78,3 ± 15,1
(12,3 - 590,9) (5,3 - 595,4)
(N= 56) (N= 55)
Anti-AGG 2 + 3 - IgG 418,37 ± 210,1 539,9 ± 300,2
(16,2 -11603,1) (0,6 -14156,2)
(N= 55) (N= 54)
* Geometric mean titre ± standard error of the mean.
The anti-FHA GMT was relatively high at birth and then
declined steadily throughout the period of vaccination. Mter
three doses of the vaccine, i.e. at 9 months of age, a ~ 4-fold
rise in GMT occurred in 24,1% of subjects but a decrease
occurred in 44,9% of subjects, and 31,0% of subjects had
antibody levels which remained the same or increased only
slightly.
The anti-PT GMT fell to a nadir at 4 months of age, rose at
6 months and then fell again at 9 months (i.e. 3 months after
the third dose). There was no mean increase in antibody levels
after 3 doses of vaccine (Table IV) - 19,0% of subjects
experienced a 4-fold rise in level, 63,8% a fall, and 17,2% had
levels that remained the same or increased only slightly after 3
doses of DTP (at 9 months of age).
The three children with suspected whooping cough had a
rapid rise in levels of all three antibodies at the time of
infection (data not included). Cord blood levels of anti-PT and
anti-FHA were lower than the mean level in two cases and
higher than the mean in the third case. A response to PT and
to FHA did occur in the malnourished Children, however the
levels of antibody produced were usually lower than the mean
of the normally nourished group (data neit included).
Agglutinogens 2 + 3
There was an increase in GMT to AGG 2 + 3. IgG anti-
AGG 2 + 3 levels/fell from birth to 2 months and then rose
with each dose of vaccine (Table IV). The seroconversion rate
(a ~ 4-fold rise from pre-vaccination levels) was 67,2%.
Although the group as a whole had increased antibodies to
AGG 2 + 3, the response of individuals was absent or poor in
some cases. A decrease in GMT occurred in 16,4% of recipients;
and ·16,4% had levels that remained the same or increased only
slightly after 3 doses of vaccine (at 9 months of age). A rapid
rise in anti-AGG 2 + 3 level occurred at the time of infection
in the 3 suspected cases of whooping cough (data not provided).
The anti-AGG 2 + 3 levels in all malnourished children were
lower than the mean level (data not provided).
Discussion
The South African Whooping cough vaccine has been reponed
to be very effective in the Cape.7 In the present study this
triple vaccine with a whole-eell penussis component appeared
to be fairly safe. The children were carefully monitored for
complications and the rates of minor local and systemic post-
vaccination events were low. Only 7,6% of subjects had a lOcal
or systemic symptom whereas rates of 50% and 72% have been
reponed in some smdies in developed countries. ll,12 Fever,
the most frequently found post-vaccination event, occurred in
only 3,2% of vaccinees compared with 29,7% and 25,4%,
respectively in Japanese and Swedish smdies of whole-eell
vaccine. 13,14 Local symptoms, absent in the present smdy,
occurred in 16,7%15 - 72,2%12 of vaccinees in other smdies.
The South Mrican DTP was associated temporally with major
post-vaccination events (convulsions and hypotonic-hypo-
responsive episodes), which did not appear to produce detect-
able sequelae. The rate of convulsions (1/249 doses, i.e.
4,02/1000 doses) was high compared with other DTP vaccine
smdies in the UK (0,4/1000 doses)16 and the USA (0,57/1 000
doses).2 In our smdies of acellular penussis8 and measles
vaccines among black children in South Mrica (unpublished
observations) rates of convulsions were 1,7/1000 and 0/136
doses, respectively. Therefore this post-vaccination event
appears to be related to vaccination with the South Mrican
DTP.
A hypotonic-hyporesponsive episode occurred in 2 children
within 7 days after vaccination (8,03/1000 ooses). In a smdy
in the USA2 this type of reaction occurred at a rate of
0,57/1000 doses, while in our study of an acellular penussis
vaccine (to be reponed separately) this problem did not occur.
There are no data on the incidence of these events in
unvaccinated children, since it was not ethically feasible to
include such children in the study. The risk from these major
post-vaccination events cannot be fully quantified in a study of
this size and duration, panicularly as the study population had
a high incidence of infectious diseases. The possibility of these
TABLE IV. SEROLOGICAL RESPONSES TO WHOLE-CELL PERTUSSIS VACCINATION
IN INFANTS (GMT ± SEM)* (RANGE)
Pertussis IgG antibody (U)



















































• Geometric mean titre ± standard ~rror of the mean.
reactions being due to other intercurrent phenomena cannot
be excluded.
In view of the reported efficacy, it was both surprising and
interesting that serum IgG antibody responses to FHA and
PT, two tnajor antigens of B. pertussis; occurred infrequently
and that no increase in GMT of either antibody was found
after 3 doses of vaccine. Overall, a response to AGG 2 + 3 was
observed but the rate of seroconversion was only 67,2%.
Serum antibody responses to all these antigens have been
reported in immunogenicity studies of whole-eell vaccines
elsewhere. 16- 18 Also, recent trials of acellular vaccines have
shown that these confer some level of protection19,20 and have
shown that increases in serum IgG antibodies to the vaccine
antigens are a feature of the response. 14,l? However, for humans,
no serological correlates of protection against pertussis infection
have yet been discovered, although evidence for protection by
anti-PT and anti-FHA antibodies has been obtained in
mice2 \-23 and serospecific protection correlated with serum
agglutinin type has been reported18 for this species. No one
class or type of pertussis agglutinin antibody has been demon-
strated to be protective in humans and it is unknown whether
antibodies to agglutinogens alone are sufficient to confer
immunity.ll
Because of the lack of responses to FHA and PT in the
vaccinees; the high levels of all 3 antibodies found in maternal
and cord sera suggest a high prevalence of infection among
women of child-bearing age as well as active transplacental
transfer of antibody. All the tnaternal sera had substantial
levels of antibodies to FHA and to AGG 2 + 3 an4 many also
had similar levels of anti-PT (93% had anti-PT > 5 U).
However, there was 'considerable variation and this was
reflected in the cord blood antibody levels.
For I infant with suspected whooping cough, cord blood
levels of all 3 antibodies were higher than the mean cord blood
levels, whereas for the other 2 suspected cases they were
lower. The malnourished children overall responded no less
well to vaccination than did other vaccinees. Nevertheless, the
immune response was delayed in some cases and further study
of pertussis vaccination of malnourished children is needed.
This study raises serious questions about the South Mrican
whooping cough vaccine, which need to be resolved. Most
importantly a wider study of vaccine. efficacy coupled with
serological monitoring is required to determine whether the
results presented here are typical or if they arise from batch-
to-batch variability of the vaccine. The poor immunogenicity
of the DTP used in this study, at least with regard to FHA
and PT, signifies either (l) this batch would not provide
protection, contrary to expectations based on reported efficacy;
or (il) any protection was likely to be due to some vaccine
constituent(s) other than PT or FHA.
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